A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration
A Multi-center, Open-label Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-Related Macular Degeneration
Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Listed as NCT03021785, this PHASE1 trial focuses on Neovascular Age-Related Macular Degeneration and remains ongoing. Sponsored by Jiangsu T-Mab Biopharma Co.,Ltd, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Mar 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu T-Mab Biopharma Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .